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The FMR1 protein product, FMRP, is an mRNA binding protein associated with translational
inhibition of target transcripts. One FMRP target is the amyloid precursor protein (APP)
mRNA, and APP levels are elevated in Fmr1 KO mice. Given that elevated APP protein
expression can elicit Alzheimer’s disease (AD) in patients and model systems, we
evaluated whether FMRP expression might be altered in Alzheimer’s autopsy brain
samples and mouse models compared to controls. In a double transgenic mouse model
of AD (APP/PS1), we found no difference in FMRP expression in aged AD model
mice compared to littermate controls. FMRP expression was also similar in AD and
control patient frontal cortex and cerebellum samples. Fragile X-associated tremor/ataxia
syndrome (FXTAS) is an age-related neurodegenerative disorder caused by expanded CGG
repeats in the 5′ untranslated region of the FMR1 gene. Patients experience cognitive
impairment and dementia in addition to motor symptoms. In parallel studies, we measured
FMRP expression in cortex and cerebellum from three FXTAS patients and found reduced
expression compared to both controls and Alzheimer’s patient brains, consistent with
animal models. We also find increased APP levels in cerebellar, but not cortical, samples
of FXTAS patients compared to controls. Taken together, these data suggest that a
decrease in FMRP expression is unlikely to be a primary contributor to Alzheimer’s disease
pathogenesis.
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INTRODUCTION
Fragile X-associated disorders result from intergenerational insta-
bility in a CGG microsatellite repeat expansion located in the 5′
untranslated region (UTR) of the fragile X mental retardation
(FMR1) gene. In the general population, the mean repeat length
is 30 CGG repeats with a range from 4 to 55 (Strom et al.,
2007). When this repeat expands beyond this normal range, it
can cause symptoms associated with fragile X spectrum disorders
(Renoux and Todd, 2012; Nelson et al., 2013). Greater than 200
CGG repeats elicits transcriptional silencing of the FMR1 locus,
with absent or markedly reduced FMR1 mRNA and FMR pro-
tein (FMRP) production (Bagni and Oostra, 2013). These large
expansions result clinically in fragile X syndrome (FXS), which
is the most common monogenic cause of autism and intellectual
disability (Rogers et al., 2001; Hernandez et al., 2009).
In contrast, repeat expansions in the “premutation” range
between 55 and 200 CGG repeats cause a distinct set of human
disorders, including fragile X-associated tremor/ataxia syndrome
(FXTAS) and fragile X-associated Premature Ovarian Insuffi-
ciency (FXPOI; Berry-Kravis et al., 2007; Hagerman, 2013; Nelson
et al., 2013). FXTAS is an age-related neurodegenerative disor-
der characterized by gait difficulties, action tremor, and vari-
ably present Parkinsonism, dysautonomia, and dementia (Berry-
Kravis et al., 2007). Unlike the scenario in FXS, premutation
sized CGG repeats elicit enhanced FMR1 transcription through
alterations in the local chromatin structure (Tassone et al., 2000a,
2007; Todd et al., 2010; Hagerman and Hagerman, 2013). How-
ever, this increase in FMR1 mRNA is paradoxically associated
with a reduction in total and activity-dependent FMRP expression
(Tassone et al., 2000b; Kenneson et al., 2001; Entezam et al.,
2007; Qin et al., 2011; Iliff et al., 2013; Ludwig et al., 2014;
Pretto et al., 2014). This decrease in FMRP likely derives from
an alteration in FMR1 mRNA translational efficiency, where
the repeat forms a hairpin secondary structure that impairs
ribosomal scanning (Feng et al., 1995; Kenneson et al., 2001;
Primerano et al., 2002; Chen et al., 2003; Ludwig et al., 2011).
Research into the mechanisms of neurodegeneration in FXTAS
has largely focused on how the FMR1 mRNA might elicit a gain
of function toxicity, either through sequestration of RNA binding
proteins or through triggered aberrant translation through the
repeat of aggregate prone proteins that underlie the intranu-
clear inclusions observed in patients (Jin et al., 2003, 2007;
Hagerman and Hagerman, 2004, 2013; Iwahashi et al., 2006;
Sofola et al., 2007; Sellier et al., 2010, 2013; Todd and Paulson,
2010; Renoux and Todd, 2012; Todd et al., 2013). However,
more recent work has begun to explore whether a reduction in
FMRP expression might contribute to aspects of disease patho-
genesis in these individuals (Iliff et al., 2013; Ludwig et al.,
2014; Pretto et al., 2014; Renoux et al., 2014; von Leden et al.,
2014).
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The absence of FMRP causes the cognitive impairment seen
in FXS and may contribute to some of the symptoms observed
in FXTAS. A significant body of work has explored the normal
functions of FMRP (O’Donnell and Warren, 2002; Santoro et al.,
2012; Wang et al., 2012). FMRP is an RNA binding protein
found associated with poly-ribosome complexes in soma and
synapses (Tamanini et al., 1996; Willemsen et al., 1996; Feng
et al., 1997; Zalfa et al., 2003; Darnell et al., 2005, 2011; Ascano
et al., 2012; Chen et al., 2014). It is normally phosphorylated,
and upon metabotropic glutamate receptor (mGluR) activation
is dephosphorylated to allow its associated transcripts to be
translated (Ceman et al., 2003; Bear et al., 2004; Weiler et al.,
2004; Muddashetty et al., 2007; Narayanan et al., 2008; Nalavadi
et al., 2012). This allows FMRP to participate in temporal and
spatial control of activity-dependent translation. In an effort
to understand how reduced levels of FMRP may alter synaptic
function, many groups have identified possible FMRP target
transcripts. One transcript associated with FMRP is the amyloid
precursor protein (APP) mRNA (Westmark and Malter, 2007; Lee
et al., 2010). High-throughput sequencing of RNAs isolated by
cross-linking immunoprecipitation (HITS-CLIP and PAR-CLIP)
analysis on FMRP-associated transcripts identified APP mRNA
(Darnell et al., 2011; Ascano et al., 2012). This interaction appears
to play a role in regulating APP translation, as APP synthesis
in response to mGluR activation is increased in control mice
(Westmark and Malter, 2007). Moreover, a mouse model of FXS
which lacks FMRP (Fmr1 KO) exhibit higher basal levels of APP,
and of the pathogenic product of APP cleavage, β-amyloid (Aβ),
and FXS patients show abnormal Aβ levels in plasma and brain
tissues (Westmark and Malter, 2007; Westmark et al., 2011).
Overexpression of APP in Fmr1 KO mice increases mortality and
seizure susceptibility (Westmark et al., 2008). Conversely, genetic
reduction of APP in the Fmr1 KO mouse improved seizure activ-
ity, anxiety-associated behavior, spine morphology, and altered
mGluR-dependent long-term depression (LTD), indicating a role
for Aβ expression levels in FXS pathology (Westmark et al.,
2011).
As there is evidence indicating FMRP participates in regulating
APP production and that FMRP and APP interact genetically,
we sought to explore the possibility that reduced FMRP levels
may contribute to increased APP and Aβ levels in AD mouse
models and spontaneous cases of AD. This is especially relevant
given evidence for decreased FMRP expression with age in mouse
models (Singh et al., 2007; Iliff et al., 2013; Gaur and Prasad, 2014;
Ludwig et al., 2014). Impaired FMRP expression in older individ-
uals could lead to increased basal APP translation, increasing the
amyloidogenic burden and thus serving as a contributor to AD
pathogenesis. We sought to test this hypothesis by measuring cor-
tical FMRP levels by western blot and immunohistochemistry in a
double transgenic AD mouse model (APP/PS1; Haass et al., 1995;
Prihar et al., 1999). We also measured FMRP immunoreactivity
in human cortex and cerebellum from control and confirmed AD
samples. Concurrently, we included samples from three FXTAS
patients who exhibited reduced FMRP levels. We found similar
FMRP expression in AD model mice and AD human samples.
We further examined APP expression in FXTAS patient samples,
and found a selective increase in cerebellar lysates, but not
in frontal cortex or in CGG KI model mice. Taken together,
our data suggest that impaired FMRP expression is unlikely to




Animal use followed NIH guidelines and was in compliance
with the University of Michigan Committee on Use and Care of
Animals. Fmr1 KO (Bakker et al., 1994) and CGG KI (Entezam
et al., 2007) mice were genotyped as described previously (Iliff
et al., 2013; Renoux et al., 2014). APP/PS1 mouse (Haass et al.,
1995; Prihar et al., 1999) genotypes were confirmed with western
analysis for the human APP transgene (clone 6E10 1:2000; Milli-
pore).
PATIENT DONOR SAMPLES
All human tissues were obtained and distributed under oversight
by appropriate institution specific review boards. Frontal cortex
and cerebellar tissue from 10 control and 10 clinically probable
AD patients were obtained from the University of Michigan
Alzheimer’s Disease Brain Bank. All AD cases were confirmed
at autopsy. Brain tissues from two previously described FXTAS
patients (Louis et al., 2006; Todd et al., 2013) and an additional
clinically definite FXTAS patient were used as controls for reduced
FMRP expression. CGG repeat size was determined in FXTAS
patients by DNA isolation followed by PCR using C and F
primers. See Table 1 for post-mortem interval (PMI), age, and
sex of each individual.
WESTERN BLOT ANALYSIS
Western blotting was performed as described previously (Iliff
et al., 2013). Briefly, brain tissue samples (cerebral cortex and
subcortical regions from mice, or frontal cortex from human,
and cerebellum) were homogenized in RIPA buffer containing
Complete Mini protease inhibitor cocktail (Roche). Samples were
sonicated and centrifuged, and total protein content of the super-
natant measured using a DC Protein assay (Bio-Rad). Equal
amounts of protein were mixed with 6× Laemmli buffer and
boiled for 5 min before separation on 8% polyacrylamide gels.
Gels were transferred and blocked with Tris-buffered saline con-
taining 0.1% Triton-X (TBST) and 5% non-fat milk for 60 min at
room temperature (RT), and incubated with an antibody against
FMRP (Millipore mouse monoclonal 1C3 1:1000 or Abcam rabbit
polyclonal 17722, 1:1000), or against the C-terminus of APP
(Invitrogen 51-2700, 1:500) and β-tubulin (University of Iowa’s
Developmental Studies Hybridoma Bank E7, 1:5000) overnight
at 4◦C. Blots were incubated with corresponding fluorescent sec-
ondary antibody (1:15000; IRDye® 680RD or 800CW, LI-COR)
for 60 min at RT, and imaged with the Odyssey® Imaging System
(LI-COR).
Band intensity was quantified in the linear range with den-
sitometry using LI-COR Image StudioTM Software. Experi-
ments were performed in technical triplicate, and FMRP/tubulin
or APP/tubulin ratios to two control samples included in
every experiment were combined. These ratios were averaged,
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Table 1 | Patient donor information.
Diagnosis Sex Age PMI (hours) FMR1 repeats
Control F 82 21 n.d.
Control M 39 22 n.d.
Control M 47 23 n.d.
Control M 69 24 n.d.
Control M 72 23 n.d.
Control F 86 18 n.d.
Control F 87 9 n.d.
Control F 74 6 n.d.
Control M 59 12 n.d.
Control M 81 6 n.d.
AD F 78 2 n.d.
AD M 69 12 n.d.
AD F 75 24 n.d.
AD F 66 9 n.d.
AD M 82 9 n.d.
AD M 73 3 n.d.
AD F 86 15 n.d.
AD M 80 21 n.d.
AD F 75 24 n.d.
AD M 69 13 n.d.
FXTAS M 78 3.5 90 CGGs
FXTAS M 74 3 102 CGGs
FXTAS M 80 6.5 116 blood/180 cheek
Diagnosis, age at death, post-mortem interval (PMI) in hours for all patients, and
FMR1 5′ UTR CGG length for FXTAS patients included above. n.d. indicates not
determined.
normalized to control values for each experiment, and expressed
as %control in experiments.
IMMUNOHISTOCHEMISTRY
Antibody control experiments were performed on mice aged
50–75 weeks (n = 6 WT, n = 5 CGG KI, n = 1 Fmr1 KO),
and experimental analysis on 80- to 90-week-old mice (n = 2
WT, n = 3 APP/PS1) which were anesthetized with 0.2 mg
ketamine/20 µg xylazine per kilogram prior to transcardial per-
fusion with 15–20 mL phosphate buffered saline (PBS) and 15–
20 mL 4% paraformaldehyde (PFA) in PBS. Brains were dissected,
fixed overnight in 4% PFA, and then sunk in 30% sucrose in PBS
at 4◦C. Brains were sectioned at 30µm and placed in a cryostorage
solution of 30% sucrose/33.33 % ethylene glycol/0.05 M PBS until
needed.
Prior to staining, slices were rotated in PBS overnight at 4◦C
to remove cryostorage solution, then basic antigen retrieval was
performed by placing the slices in 0.01 M sodium citrate (pH 8.5)
at 80◦C for 10 min followed by three 5-min washes in PBS. The
slices were then placed in 1% H2O2 in Tris to block endogenous
peroxidases. Slices were permeabilized in 0.1% Triton-X/.05%
bovine serum albumin (BSA) in Tris for 30 min at RT and blocked
in 5% normal goat serum (NGS) for 1 h at RT. Slices were then
incubated overnight in anti-FMRP antibody (1:3500). Following
two washes, slices were incubated in horseradish peroxidase-
conjugated secondary antibody (1:1000) in 5% NGS in Tris.
Prior to peroxidase development, slices were treated with the
Vectastain ABC kit (Vector) to increase diaminobenzidine (DAB)
visibility. Following washes, slices from all genotypes were placed
simultaneously in ImmPACT DAB solution (Vector) for 10–15 s
until they just started to turn brown. Following washes, slices were
mounted, allowed to dry overnight then either counterstained in
Gill’s 1:2 hematoxylin for 45–60 s, or immediately dehydrated in
an alcohol gradient and mounted.
MICROSCOPY
A slide scanning microscope (Zeiss) was used to image all DAB
stained tissue. Fields of view were selected in the hippocampus
and cortex to be easily reproducible across multiple sections.
Images were taken using the same exposure settings for all geno-
types.
STATISTICAL ANALYSIS
All values are expressed as the mean± standard error of the mean.
Western blot immunoreactivity for each sample was measured in
technical triplicate, and combined as a ratio of %control for each
blot. These combined values were averaged, and compared using
a Student’s t-test, with significance indicated by a P-value < 0.05.
FMRP expression compared to age, PMI, and pH were evalu-
ated using a Pearson’s correlation coefficient on combined cortical
and cerebellar FMRP values from either control and AD samples,
or combined control and FXTAS cortical and cerebellar values,
with significance indicated by P < 0.05. Comparison of donor
gender in FMRP expression was performed using a two-way
ANOVA with post hoc Sidak’s multiple comparison test.
RESULTS
To accurately evaluate the expression of FMRP in our experi-
ments, we compared two commonly used antibodies for their
specificity by western blot and immunohistochemistry. To assess
the sensitivity of each antibody, we compared FMRP levels in
WT, littermate CGG KI, and Fmr1 KO mouse cortical lysates
(Figure 1). Both the 1C3 mouse anti-FMRP (Millipore) and the
17722 rabbit anti-FMRP (Abcam) show reactivity in the Fmr1 KO
samples (Figures 1A,B). The largest band at∼75 kD corresponds
to FMRP and is absent in Fmr1 KO lysates with both antibodies.
This band was used for all measurements in subsequent figures.
However, a smaller band at∼71 kD which results at least partially
from cross-reactivity with the related protein, FXR1 (Tamanini
et al., 1997; Ceman et al., 1999), is still reactive with both anti-
bodies tested. Similarly, we examined specificity of the 17722 anti-
FMRP antibody in WT, CGG KI and Fmr1 KO coronal brain
sections by immunohistochemistry (WT n = 3, CGG KI n = 3,
Fmr1 KO n= 4; representative images; Figures 1C,D). Conditions
were optimized to minimize DAB reactivity in Fmr1 KO tissue.
We reliably observed reduced FMRP levels in CGG KI mice both
by western analysis and immunohistochemistry, consistent with
previous reports (Tassone et al., 2000a; Kenneson et al., 2001;
Entezam et al., 2007; Qin et al., 2011; Iliff et al., 2013; Ludwig
et al., 2014; Pretto et al., 2014; Figure 1).
In an effort to probe a potential role of altered FMRP expres-
sion in AD pathogenesis, we evaluated FMRP in a double trans-
genic model of AD which contains an additional copy of the
human APP gene carrying the familial Swedish (K670N/M671L)
missense mutation (Haass et al., 1995), and a deletion of exon 9 in
the presenilin1 gene (Prihar et al., 1999). These double transgenic
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FIGURE 1 | FMRP antibody specificity. (A) Mouse α-FMRP 1C3 (Millipore)
1:250 on cerebellar and combined cerebral cortex and subcortical brain
lysates of WT (n = 2), premutation model CGG KI (n = 2), and Fmr1 KO
mice (n = 2). Arrow indicates the FMRP-specific band which is absent in
Fmr1 KO lysates. (B) Rabbit α-FMRP 17722 (Abcam) 1:1000 on the same
brain lysates as in (A). (C) Immunohistochemistry with the 17722 α-FMRP
antibody in WT (n = 3), CGG KI (n = 3) and Fmr1 KO (n = 4) hippocampus.
(D) Cortical FMRP expression from identical animals as in (C) stained with
the 17722 antibody. Sections were counter-stained with hematoxylin to
label nuclei.
mice (APP/PS1; n = 6: 6 females) and age-matched control
littermates (n = 8: 4 males, 4 females) were compared at 80–90
weeks of age for combined cortical and subcortical FMRP levels.
We performed western blot analysis in triplicate, averaging the
percent control FMRP for each animal across blots to minimize
error between experiments. We find no difference in FMRP levels
in APP/PS1 mice compared to controls (t = 0.358, df = 12, NS;
Figure 2A). Cerebellar samples from the same animals demon-
strated no significant difference in FMRP expression (t = 1.300,
df= 12, NS; Figure 2A). Any contribution of sex was evaluated in
the control animals (as the APP/PS1 mice were all female), and
FMRP expression was not significantly different between male
and female control cortical values (male n = 4, female n = 4,
t = 0.717, df = 6, NS; data not shown). As several groups have
found FMRP levels change with age (Singh et al., 2007; Iliff et al.,
2013; Gaur and Prasad, 2014; Ludwig et al., 2014), we explored
expression in young (8-week-old) APP/PS1 mice (WT n = 3: 3
females; APP/PS1 n= 3: 3 females). We find no difference in corti-
cal FMRP expression at this age (t = 0.919, df= 4, NS). Cerebellar
FMRP expression demonstrated a non-significant increase in AD
model mice (t = 2.627, df= 4, NS; Figure 2B). We also compared
age-dependent FMRP expression of the 8-week-old and the 80-
week-old animals, and did not find a significant difference in the
cortex or the cerebellum (cortex: 8 weeks, n= 3 females; 80 weeks
n = 8, 4 males, 4 females; t = 0.342, df = 9, NS; cerebellum:
8 weeks n = 3 females; 80 weeks n = 8, 4 males, 4 females;
t = 1.188, df = 9, NS; Figure 2C). There was no significant
difference between same sex 8- and 80-week-old female FMRP
expression (cortex: 8 weeks female n = 3, 80 weeks female n = 4,
t = 1.034, df= 5, NS; cerebellum: 8 weeks female n= 3, 80 weeks
female n= 4, t = 1.136, df= 5, NS; data not shown). We went on
to probe FMRP levels by immunohistochemistry in 80-week-old
FIGURE 2 | FMRP expression in AD model APP/PS1 mice. (A) Cortical
and subcortical, and cerebellar lysates from 80-week-old APP/PS1 (n = 6)
and age-matched controls (n = 8) probed with the 17722 α-FMRP antibody
and actin or tubulin. (A1) FMRP/actin values were calculated and
normalized to WT levels, and expressed as %WT in the quantification.
Results are the summary of values calculated in technical triplicate. (B)
Eight-week-old APP/PS1 (n = 3) and WT littermate controls (n = 3) were
compared for FMRP expression in cortical and subcortical and cerebellar
lysates. (B1) FMRP/tubulin values are expressed as %WT, and data are the
summary of experiments performed in technical triplicate. (C)
Eight-week-old WT (n = 3) and 80-week-old WT (n = 8) cortical and
cerebellar lysates compared for FMRP expression. (C1) FMRP/tubulin
values are expressed as percentage of mean 8-week-old samples, and data
are the summary of experiments performed in duplicate. (D) Hippocampal
FMRP expression using the 1C3 α-FMRP antibody in WT and APP/PS1
mice. (E) Cortical FMRP in the same mice as in (D).
control and APP/PS1 mice. Comparing cortex, hippocampus,
and subcortical regions using the 1C3 α-FMRP antibody, there
were no differences detected (WT n = 2, APP/PS1 n = 3;
Figures 2D,E).
As the mouse model we used was genetically modified to
mimic some AD phenotypes, it may not recapitulate proximal
pathogenic events that contribute to spontaneous cases of AD.
In an attempt to better answer the question of a possible role
for FMRP in AD development, we obtained frontal cortex and
cerebellar autopsy samples from control and AD patients (details
included in Table 1). As with our murine samples, we performed
western blot analysis in technical triplicate to minimize variabil-
ity in our measurements. Using this technique, we found no
difference in FMRP expression level in the frontal cortex
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(t = 0.2836, df = 18, NS; control n = 10, AD n = 10;
Figures 3A,C). As two of the control individuals were younger
than the majority of the other donors (39 and 47 years old), we
performed analysis excluding those values, and found no change
in the result (t = 0.3915, df = 16, NS). Similarly there was no
difference in FMRP expression found in the cerebellar samples
analyzed (t = 0.2837, df = 18, NS; control n = 10, AD n = 10;
Figures 3B,C). Again, excluding the youngest individuals did not
impact the finding (t = 0.3618, df = 16; NS). As there was a
wide range in PMI and age of the samples tested, we compared
normalized values against these two variables, in addition to tissue
pH (where available), and found a significant impact on FMRP
levels with longer PMI (age: r = −0.111, df = 38, NS; PMI:
r = −0.371, df = 38, P < 0.05; pH: r = 0.277, df = 22, NS;
Figure 3D, data not shown). We also evaluated the impact of
gender in this experiment by comparing the data with a two-way
ANOVA, and found no significant difference of FMRP expression
in any group in the cortex [gender: F(1,16) = 0.3187, NS; diag-
nosis: F(1,16) = 0.05139, NS; interaction: F(1,16) = 0.02455, NS;
FIGURE 3 | FMRP expression in Alzheimer’s disease cortex and
cerebellum. (A) Frontal cortex lysates from control (n = 10) and
autopsy-confirmed AD patients (n = 10) probed with α-FMRP 17722. (B)
Cerebellar lysates from the same patients as in (A) were evaluated
concurrently. (C) Quantification of cortical and cerebellar FMRP/tubulin
values performed in technical triplicate. (D) Normalized FMRP values were
compared to individual patient ages and post-mortem indices.
Diagnosis-independent best fit curves display overall trends in FMRP
expression.
data not shown]. Cerebellar samples similarly showed no signif-
icant impact of gender [gender: F(1,16) = 0.1176, NS; diagnosis:
F(1,16) = 0.09488, NS; interaction: F(1,16) = 0.006407, NS; data
not shown]. While these analyses only showed significant contri-
butions of PMI on FMRP levels, the negative trends of decreasing
FMRP with age and lower pH suggest that these variables should
also be controlled for in future studies.
We obtained samples from FXTAS patient brains, and com-
pared FMRP levels to the controls, finding a decrement in FMRP
immunoreactivity in two of the three samples tested, though
the number of samples evaluated was not sufficient to discern a
significant difference when the two youngest control samples were
excluded (cortex: t = 2.161, df = 9, NS; cerebellum: t = 1.793,
df= 9, NS; control n= 8, FXTAS n= 3; Figures 4A–C). Similarly,
we compared the age and PMI as a factor which may alter FMRP
levels, and found no significant difference of either variable (age:
r = −0.180, df = 24, NS; PMI: r = 0.007, df = 24, NS; data not
shown).
To further test the hypothesis that reduced FMRP might
enhance APP synthesis, we evaluated total full-length APP expres-
sion in the same FXTAS patient samples. Despite the small
sample size, we did find a selective increase in cerebellar APP
expression in FXTAS samples (t = 4.704, df = 11, P < 0.05;
control n = 10, FXTAS n = 3; Figures 5A–C). However, APP
levels were unchanged in frontal cortex samples compared to
controls (t = 0.4603, df = 11, NS; control n = 10, FXTAS n = 3;
Figures 5A–C). These results were not affected by the inclusion
of the two youngest control samples (cortex: t = 0.2636, df = 9,
NS; cerebellum: t = 4.844, df = 9, P < 0.05). This finding was
not recapitulated in 12-month-old CGG KI mice, which showed
unchanged levels of APP in both the cortex and cerebellum
(cortex: t = 1.877, df = 5, NS; cerebellum: t = 1.131, df = 5,
NS; WT n = 3, CGG KI n = 4; Figures 5D–F). To assess any
age-dependent effects of APP expression we compared CGG KI
and WT cortical and cerebellar lysates at 2 and 16–18 months
of age, and found no significant difference between genotypes
(2 months cortex: WT = 100 ± 11.66, CGG KI = 99.86 ± 21.63;
t = 0.006, df = 8, NS; WT n = 5, CGG KI n = 5; 16–18 months
FIGURE 4 | Cortical and cerebellar FMRP expression in FXTAS patients.
(A) Frontal cortex lysates from FXTAS patients (n = 3) and the same control
tissues (n = 8) probed with α-FMRP 17722. (B) Cerebellar lysates from the
same individuals as in (A). (C) Normalized FMRP expression as a percent of
controls, performed in technical triplicate.
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FIGURE 5 | Amyloid precursor protein expression in FXTAS patients
and mouse models. (A) Frontal cortex lysates from control (n = 10) and
FXTAS patients (n = 3) probed with a C-terminal αAPP antibody which
detects the three primary isoforms of full-length APP (100–125 kDa). (B)
Cerebellar lysates from the same individuals as in (A). (C) Normalized APP
expression relative to tubulin expressed as a percent of controls, performed
in technical triplicate. (D) Twelve-month-old CGG KI (n = 4) and WT
littermate control (n = 3) cortex and subcortical lysates probed with αAPP.
(E) Cerebellar lysates from the same animals as in (D). (F) Normalized APP
expression in CGG KI mice expressed as a percent of WT controls,
performed in technical triplicate. *P < 0.05 Student’s t-test.
cortex: WT = 100 ± 15.31, CGG KI = 93.09 ± 6.1; t = 0.367,
df= 5, NS; WT n= 4, CGG KI n= 3; 16–18 months cerebellum:
WT= 100± 10.84, CGG KI= 75.75± 7.70; t = 1.690, df= 5, NS;
WT n = 3, CGG KI n = 3; data not shown). The C-terminal APP
antibody used cannot detect Aβ fragments, so while total APP
levels are unchanged, the relative processing or cleavage events
may be altered.
DISCUSSION
FMRP is a synaptic mRNA binding protein implicated in fragile
X spectrum disorders. FMRP normally acts to inhibit transla-
tion of target transcripts until synaptic transmission and mGluR
activation cause its dissociation, allowing for a burst of rapid
local translation. One FMRP target is APP, the precursor to
the amyloidogenic Aβ peptide (Westmark and Malter, 2007).
APP expression is enhanced in mouse models that lack FMRP
(Westmark and Malter, 2007). FMRP expression is reported to
decline with age in mouse models and might follow a similar
trajectory in humans (Singh et al., 2007; Gaur and Prasad, 2014;
Ludwig et al., 2014). We hypothesized that a natural age-related
decline in FMRP might trigger an increase in basal APP synthesis
in neurons, leading to enhanced Aβ-42 production and possibly
serving as a proximal trigger of AD pathogenesis. Moreover,
as AD pathogenesis progresses, we hypothesized that neuronal
dysfunction and toxicity might further impair FMRP expression
and hence enhance APP translation, creating a feed-forward loop
that could drive AD pathogenesis and lower FMRP expression
in AD models and patient tissues. To test this hypothesis, we
examined FMRP expression in a double transgenic mouse model
of AD (APP/PS1), and found no significant difference between
AD model and control animals. Furthermore, we tested control
and AD patient samples, and found no difference in cortical or
cerebellar FMRP expression. In contrast, we observed a decrease
in FMRP levels in the two of the three FXTAS patients tested,
consistent with published results (Ludwig et al., 2014; Pretto et al.,
2014), and found increased cerebellar levels of APP in these same
FXTAS patients, suggesting an impact of lower FMRP on APP
expression in humans. Taken together, these data indicate that
decreased FMRP expression is not a common finding in AD and
suggests that a primary deficiency in FMRP expression is unlikely
to play a proximal role in most cases of AD. However, manipu-
lation of FMRP expression and activity retains the potential to
influence APP expression and aspects of AD pathogenesis.
FMRP’s regulatory function is dependent on phosphorylation
by S6K, and dephosphorylation by PP2A (Narayanan et al., 2007,
2008). Recent work has described a function for FMRP degra-
dation upon mGluR activation, and dephosphorylation by PP2A
(Nalavadi et al., 2012). While the goal of this study was to examine
total FMRP expression levels, alterations in FMRP phosphory-
lation would impact its regulatory function, and therefore the
control of target protein translation. While we did not observe
large alterations in FMRP levels, it is possible that relative phos-
phorylation state could play a role in AD pathogenesis. Further
studies comparing phospho-FMRP would be required to examine
this possibility.
Our group and others have observed decreases in FMRP
expression with age (Singh et al., 2007; Iliff et al., 2013; Gaur
and Prasad, 2014; Ludwig et al., 2014). However, we observed no
significant difference in FMRP levels between 8- and 80-week-old
WT mice evaluated in this study (Figure 2C). The reason for this
difference is not immediately clear, although the smaller number
of young animals evaluated and the significant variance observed
in older animals may explain the discrepancy. Other groups have
evaluated various time points ranging from neonate to adult (20
weeks of age; Singh et al., 2007; Gaur and Prasad, 2014; Ludwig
et al., 2014), and as old as 60–70 weeks of age (Singh et al., 2007;
Gaur and Prasad, 2014). Both groups have observed cerebellar
expression to steadily decrease in older animals (Gaur and Prasad,
2014; Ludwig et al., 2014), though cortical FMRP expression may
be more complex during postnatal development into adulthood
(Ludwig et al., 2014). While we and others have studied animals
near 4–6 weeks of age (Singh et al., 2007; Iliff et al., 2013; Gaur
and Prasad, 2014; Ludwig et al., 2014), the specific 8-week time
point utilized here has not been compared directly to old animals
previously.
Our study is likely underpowered to detect subtle changes in
human FMRP expression. We observed a wide range of FMRP
expression levels in both the control and patient samples, con-
sistent with published results (Ludwig et al., 2014; Pretto et al.,
2014). This variance was not completely explained by patient
age, tissue pH, or PMI (Figure 3), although all of these variables
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demonstrated a trend toward lower FMRP. This leaves open the
possibility that lower basal or activity dependent FMRP expres-
sion could still contribute to altered APP expression in a subset of
patients or in certain brain regions.
Impaired FMRP expression in FXTAS model mice and patients
have been described previously (Tassone et al., 2000a; Kenneson
et al., 2001; Entezam et al., 2007; Qin et al., 2011; Iliff et al., 2013;
Ludwig et al., 2014; Pretto et al., 2014). Similarly, we find reduced
FMRP levels in two of the three FXTAS patient samples tested
(Figure 4). Symptomatic FXTAS patients can develop cognitive
impairment in addition to motor behavior symptoms (Berry-
Kravis et al., 2007; Leehey, 2009). While early studies suggested
that pathologic hallmarks of AD are rare in FXTAS (Greco et al.,
2002), recent studies in female premutation carriers with demen-
tia demonstrated plaque and neurofibrillary tangle development
consistent with AD pathology (Tassone et al., 2012). However, a
recent study examining AD patient populations for FMR1 CGG
expansions did not find a significant association (Hall et al., 2014).
To test whether FMRP insufficiency might lead to increased
APP synthesis in FXTAS, we evaluated APP levels in our patient
samples (Figure 5). We detected an increase in cerebellar, but not
cortical APP expression in FXTAS patients and no differences in a
mouse model of FXTAS (Figure 5). The C-terminal antibody used
for this study does not detect Aβ fragments, so it remains possible
that APP processing is altered in FXTAS or CGG premutation
models. However, in the context of the published studies noted
above, a strong direct relationship between CGG repeats and
induction of amyloid pathology appears unlikely.
The group 1 mGluR, mGluR5, has been identified as a receptor
of the APP peptide Aβ42 (Renner et al., 2010; Sokol et al.,
2011; Um et al., 2013; Hamilton et al., 2014). A recent report
explored the role of increased mGluR5 signaling in the double
transgenic APP/PS1 model of AD (Hamilton et al., 2014). Genetic
modulation of mGluR5 improved behavioral learning perfor-
mance, and decreased amyloid plaques found in the APP/PS1
mice (Hamilton et al., 2014). Furthermore, cortical FMRP expres-
sion was increased in 12-month-old APP/PS1 mice compared to
WT controls, presumably due to increased mGluR5 signaling,
which generates a positive feedback loop leading to increased APP
production and cleavage (Hamilton et al., 2014). The reason for
differing results in our study is not entirely clear, however, the ani-
mals examined in this report were significantly older (18 months
old compared to 12 months old), and the procedures for tissue
isolation and lysate generation were different (Hamilton et al.,
2014). Of note, the increase observed in Hamilton et al. (2014) is
consistent with our observations of human AD cerebellar samples
which showed increased FMRP expression compared to controls
(Figure 3).
While reduced FMRP might contribute to neuronal dysfunc-
tion in FXTAS patients, it is unlikely to be a primary cause of neu-
rodegeneration in FXTAS. Expression of CGG repeats as RNA in
heterologous contexts is sufficient to elicit toxicity in Drosophila,
cells, and mice (Jin et al., 2003, 2007; Hagerman and Hagerman,
2004; Iwahashi et al., 2006; Sofola et al., 2007; Hashem et al., 2009;
Sellier et al., 2010, 2013; Todd and Paulson, 2010; Renoux and
Todd, 2012; Hagerman, 2013). However, FMRP insufficiency may
nonetheless contribute to the cognitive decline observed in mouse
models and patients with FXTAS. In addition to the potential
differential amyloidogenic burden, reduced FMRP likely impacts
synaptic function in premutation mouse models (Hunsaker et al.,
2012; Iliff et al., 2013; von Leden et al., 2014). Synaptic dysregu-
lation is thought to precede neurodegeneration, and contribute
to the onset of symptoms prior to gross neuronal loss (Dong
et al., 2009; Milnerwood and Raymond, 2010). Delineating the
role of FMRP insufficiency in FXTAS thus remains an important
objective going forward given the implications for therapeutic
development in patients.
In summary, we find no evidence to support a direct link
between lower basal FMRP expression and AD pathogenesis.
Future work will be needed to define whether changes in FMRP
activity influence AD development, given the known roles of
FMRP in APP processing and neuronal function.
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